K. S. Hamel

Suggest Changes
Learn More
4721 Background: ATN, an oral ET antagonist with high selectivity for ETA receptor, is in phase 3 clinical development for the treatment of HRPC. ETA receptors are primarily responsible for ET-1(More)
  • 1